Approval Date: May 2022
A steroid-free topical indicated for treatment of plaque psoriasis
Approval Date: May 2022
Indicated for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, and other assistance with breathing
Approval Date: May 2022
Indicated for the improvement of glycemic control in patients with type 2 diabetes, in conjunction with diet and exercise
Approval Date: Apr 2022
Indicated for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder
Approval Date: Mar 2022
A first-time generic for Vimpat, this drug treats partial onset seizures
Approval Date: Mar 2022
Indicated for the treatment of mild-to-severe dementia of the Alzheimer’s type. This product is the first transdermal patch for this indication.
Approval Date: Mar 2022
A first-time generic for Symbicort, this drug is indicated for the treatment of COPD and asthma.
Approval Date: Feb 2022
A first-time generic for Farxiga, a medication used to treat type 2 diabetes, as well as adults with certain kinds of heart failure chronic kidney disease.
Approval Date: Feb 2022
A first-time generic of Revex, this drug is indicated for the complete or partial reversal of opioid drug effects, including respiratory depressions from natural or synthetic opioids, and for the management of opioid overdose
Approval Date: Feb 2022
Indicated for the treatment of chronic angina, a type of chest pain caused by reduced blood flow to the heart.
